TNF-α blockers in inflammatory bowel diseases: Practical consensus recommendations and a user's guide

Swiss Medical Weekly

Volumn 139, Issue 19-20, 2009, Pages 278-287

  Pache, Isabelle ^a   Rogler, Gerhard ^b   Felley, Christian ^a,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CHICKENPOX VACCINE; CIPROFLOXACIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; ETANERCEPT; GLUCOCORTICOID; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLIXIMAB; INFLUENZA VACCINE; ISONIAZID; JAPANESE ENCEPHALITIS VACCINE; MALARIA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; TICK BORNE ENCEPHALITIS VACCINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TYPHOID VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ALCOHOL LIVER DISEASE; ANKYLOSING SPONDYLITIS; BLOOD EXAMINATION; CHEMOPROPHYLAXIS; CHICKENPOX; CLINICAL TRIAL; COLITIS; COLON CROHN DISEASE; CONTRACEPTION; CROHN DISEASE; DIPHTHERIA; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; EPIDEMIC ENCEPHALITIS; FECES ANALYSIS; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INTESTINE FISTULA; LACTATION; MALARIA; MEASLES; MENINGOCOCCOSIS; MUMPS; NOTE; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PREGNANCY; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RABIES; RHEUMATOID ARTHRITIS; RUBELLA; SCREENING; TETANUS; TICK BORNE ENCEPHALITIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUBERCULOSIS; TYPHOID FEVER; ULCERATIVE COLITIS; URINALYSIS; VACCINATION; VERRUCA VULGARIS; YELLOW FEVER;

EID: 67650079131     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (53)

1. Economou M. Pappas G. New global map of Crohn's disease: Genetic, environmental, and socioeconomic correlations Inflammatory Bowel Diseases 2008 14 5 709-720 DOI 10.1002/ibd.20352 1 Economou M, Pappas G. New global map of Crohn's disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14:709-720 (Pubitemid 351742998)
2. Wallis R. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601-611
3. Peyrin-Biroulet L. Deltenre P. de Suray N. Branche J. Sandborn W.J. Colombel J. Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials Clinical Gastroenterology and Hepatology 2008 6 6 644-653 DOI 10.1016/j.cgh.2008.03.014, PII S1542356508002917 3 Peyrin-Biroulet L, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653 (Pubitemid 351783447)
4. Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion Drug Safety. 2008; (5):617-632
5. Rutgeerts P. Van Assche G. Vermeire S. Optimizing Anti-TNF treatment in inflammatory bowel disease Gastroenterology 2004 126 6 1593-1610 DOI 10.1053/j.gastro.2004.02.070 5 Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004; 126(6): 1593-1610 (Pubitemid 38649876)
6. Hamon M, et al. Demyelinating neuropathy during an anti-TNF-alpha treatment with review of the literature. Rev Neurol. 2007;163(12):1232-1235
7. Nathan D.M. Angus P.W. Gibson P.R. Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: Guidelines for clinical approach Journal of Gastroenterology and Hepatology 2006 21 9 1366-1371 DOI 10.1111/j.1440-1746.2006.04559.x 7 Nathan D, Angus PP, Gibson R. Hepatitis B and C virus infections and anti-tumor necrosis factor-α therapy: Guidelines for clinical approach. J Gastroenterl Hepatol. 2006;21(9):1366-1371 (Pubitemid 44154702)
8. Viget N, et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57(4):549-558
9. Travis S.P.L. Stange E.F. Lemann M. Oresland T. Chowers Y. Forbes A. D'Haens G. Kitis G. Cortot A. Prantera C. Marteau P. Colombel J.-F. Gionchetti P. Bouhnik Y. Tiret E. Kroesen J. Starlinger M. Mortensen N.J.McM. European evidence based consensus on the diagnosis and management of Crohn's disease: Current management Gut 2006 55 SUPPL. 1 i16-i35 DOI 10.1136/gut.2005.081950b 9 Travis SPL, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55(Suppl-1):i16-35. (Pubitemid 43268291)
10. Ben-Ami H. Ginesin Y. Behar D.M. Fischer D. Edoute Y. Lavy A. Diagnosis and treatment of urinary tract complications in Crohn's disease: An experience over 15 years Canadian Journal of Gastroenterology 2002 16 4 225-229 10 Ben-Ami H, Claudepierre P, Behar D. Diagnosis and treatment of urinary tract complications in Crohn's disease: an experience over 15 years. Can J Gastroenterol. 2002;16:225-229 (Pubitemid 34727587)
11. Schoepfer A, et al. Comparison of Interferon-Gamma Release Assay Versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease. Am J Gastroenterol. 2008;103(11):2799-2806
12. Beglinger C. Dudler J. Mottet C. Nicod L. Seibold F. Villiger P.M. Zellweger J.-P. Screening for tuberculosis infection before initiation of anti-TNF-α therapy Swiss Medical Weekly 2007 137 43 44 621-622 12 Beglinger C, et al. Screening for tuberculosis infection before initiation of an anti-TNF-alpha therapy. Swiss Med Weekly. 2007;137 (43):620-623 (Pubitemid 350114753)
13. Crum N.F. Lederman E.R. Wallace M.R. Infections associated with tumor necrosis factor-α antagonists Medicine 2005 84 5 291-302 DOI 10.1097/01.md.0000180044.19285.9a 13 Crum N, Lederman E, Wallace M. Infections associated with tumor necrosis factor-alpha antagonists. Medicine. 2005;84(5):291-302. (Pubitemid 41368482)
14. Naveau S. Chollet-Martin S. Dharancy S. Mathurin P. Jouet P. Piquet M.-A. Davion T. Oberti F. Broet P. Emilie D. A Double-Blind Randomized Controlled Trial of Infliximab Associated with Prednisolone in Acute Alcoholic Hepatitis Hepatology 2004 39 5 1390-1397 DOI 10.1002/hep.20206 14 Naveau S, et al. A double-blind randomized controlled trial of in- fliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39(5):1390-1397 (Pubitemid 38569061)
15. Boetticher N, et al. Randomized, double-blinded, placebo controlled multi-center trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;134:A-765.
16. Venkatesan T, et al. Abnormal PAP smears, cervical dysplasia and immunomodulator therapy in women with inflammatory bowel disease. Gastroenterology. 2006;130(A3).
17. Kane S, Khatibi B, Reddy B. Higher Incidence of Abnormal Pap Smears in Women With Inflammatory Bowel Disease. Am J Gastroenterology. 2008;103(3):631-636
18. Melmed G.Y. Ippoliti A.F. Papadakis K.A. Tran T.T. Birt J.L. Lee S.K. Frenck R.W. Targan S.R. Vasiliauskas E.A. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses American Journal of Gastroenterology 2006 101 8 1834-1840 DOI 10.1111/j.1572-0241.2006.00646.x 18 Melmed G, et al. Patients with Inflammatory Bowel Disease Are at Risk for Vaccine-Preventable Illnesses. Am J Gastroenterology. 2006;101(8):p.1834-1840 (Pubitemid 44166594)
19. Sands B.E. Cuffari C. Katz J. Kugathasan S. Onken J. Vitek C. Orenstein W. Guidelines for immunizations in patients with inflammatory bowel disease Inflammatory Bowel Diseases 2004 10 5 677-692 DOI 10.1097/00054725-200409000- 00028 19 Sands B, et al. Guidelines for immunization in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;2004(5):677-692 (Pubitemid 39276481)
20. Kapetanovic MC, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology. 2006;45(1):106-111
21. Gelinck L.B.S. Van Der Bijl A.E. Beyer W.E.P. Visser L.G. Huizinga T.W.J. Van Hogezand R.A. Rimmelzwaan G.F. Kroon F.P. The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination Annals of the Rheumatic Diseases 2008 67 5 713-716 DOI 10.1136/ard.2007.077552 21 Gelinck LBS, et al. The effect of anti-tumour necrosis factor {alpha} treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;6 (5):713-716 (Pubitemid 351571939)
22. Vonkeman H. Ten Napel C. Rasker H. Van De Laar M. Disseminated primary varicella infection during infliximab treatment Journal of Rheumatology 2004 31 12 2517-2518 22 Vonkeman H, et al. Disseminated primary varicella infection during infliximab treatment. J Rheumatology. 2004;31:2517-2518 (Pubitemid 39603107)
23. Mahadevan U. Kane S. Sandborn W.J. Cohen R.D. Hanson K. Terdiman J.P. Binion D.G. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease Alimentary Pharmacology and Therapeutics 2005 21 6 733-738 DOI 10.1111/j.1365-2036.2005.02405.x 23 Mahadevan U, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Alimentary Pharmacology & Therapeutics, 2005;21(6):733-738 (Pubitemid 40469001)
24. Schnitzler F, et al. Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease. Gut. 2007;56(Suppl III):A24.
25. Katz J.A. Antoni C. Keenan G.F. Smith D.E. Jacobs S.J. Lichtenstein G.R. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis American Journal of Gastroenterology 2004 99 12 2385-2392 DOI 10.1111/j.1572-0241.2004.30186.x 25 Katz JA, et al. Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid Arthritis. Am J Gastroenterology. 2004;99(12):2385-2392 (Pubitemid 40039370)
26. Vasiliauskas E, et al. Case Report: Evidence for Transplacental Transfer of Maternally Administered Infliximab to the Newborn. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, 2006;4(10):1255-1258
27. D'Haens G. Baert F. van Assche G. Caenepeel P. Vergauwe P. Tuynman H. De Vos M. van Deventer S. Stitt L. Donner A. Vermeire S. Van De Mierop F.J. Coche J.-C.R. van der Woude J. Ochsenkuhn T. van Bodegraven A.A. Van Hootegem P.P. Lambrecht G.L. Mana F. Rutgeerts P. Feagan B.G. Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial The Lancet 2008 371 9613 660-667 DOI 10.1016/S0140-6736(08)60304-9, PII S0140673608603049 27 D'Haens G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667 (Pubitemid 351284485)
28. Baert F. Noman M. Vermeire S. Van Assche G. D'Haens G. Carbonez A. Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease New England Journal of Medicine 2003 348 7 601-608 DOI 10.1056/NEJMoa020888 28 Baert F, et al. Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease. N Engl J Med. 2003; 348(7):601-608 (Pubitemid 36204954)
29. Hanauer S.B. Feagan B.G. Lichtenstein G.R. Mayer L.F. Schreiber S. Colombel J.F. Rachmilewitz D. Wolf D.C. Olson A. Bao W. Rutgeerts P. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial Lancet 2002 359 9317 1541-1549 DOI 10.1016/S0140-6736(02)08512-4 29 Hanauer SB, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541-1549 (Pubitemid 34621118)
30. Hanauer S.B. Wagner C.L. Bala M. Mayer L. Travers S. Diamond R.H. Olson A. Bao W. Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease Clinical Gastroenterology and Hepatology 2004 2 7 542-553 DOI 10.1016/S1542-3565(04) 00238-1, PII S1542356504002381 30 Hanauer S, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2(7):542-553 (Pubitemid 38834038)
31. Mackey A.C. Green L. Liang L.-C. Dinndorf P. Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease Journal of Pediatric Gastroenterology and Nutrition 2007 44 2 265-267 DOI 10.1097/MPG.0b013e31802f6424, PII 0000517620070200000019 31 Mackey A, Green L, Liang L. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267 (Pubitemid 46175082)
32. Van Assche G. Magdelaine-Beuzelin C. D'Haens G. Baert F. Noman M. Vermeire S. Ternant D. Watier H. Paintaud G. Rutgeerts P. Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial Gastroenterology 2008 134 7 1861-1868 DOI 10.1053/j.gastro.2008.03.004, PII S0016508508004356 32 Van Assche G, et al. Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial. Gastroenterology. 2008;134(7):1861-1868 (Pubitemid 351790744)
33. Maser E.A. Villela R. Silverberg M.S. Greenberg G.R. Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn's Disease Clinical Gastroenterology and Hepatology 2006 4 10 1248-1254 DOI 10.1016/j.cgh.2006.06.025, PII S154235650600677X 33 Maser E, et al. Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn's Disease. Clin Gastroenterol Hepatol. 2006;4(10): 1248-1254 (Pubitemid 44512213)
34. Karmiris K, et al. Adalimubab trough serum levels and clinical response in a single-center cohort of inflammatory bowel disease patients: can trough serum levels serve as a predictor for future loss of response? Gastroenterology. 2008;134(Suppl 1):A-68.
35. Karmiris K, et al. A 3-week course of 0 mg weekly administered adalimubab as a rescue therapy for patients with Crohn's disease who lost response to 40 mg weekly: relationships with adalimubab trough serum levels. Gastroenterology. 2008;134(Suppl 1):A-640.
36. Feagan B, et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Gut. 2008;57(Suppl II):p. A66.
37. Schnitzler F, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-center cohort. Gut. 2009;58:492-500.
38. Lichtenstein G, et al. Safety of infliximab and other Crohn's disease therapies - Treat registry data with nearly 15,000 patients-years of follow-up. Gastroenterology. 2006;130:A-71.
39. Fidder H, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501-508
40. Thia K, et al. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008;103: 3123-3131
41. Toruner M, et al. Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease. Gastroenterology. 2008; 134(4):929-936
42. Geraghty EM, et al. Overwhelming Parasitemia with Plasmodium falciparum Infection in a Patient Receiving Infliximab Therapy for Rheumatoid Arthritis. Clin Infect Dis. 2007;44(10):e82-e84.
43. Rutgeerts P. Feagan B.G. Lichtenstein G.R. Mayer L.F. Schreiber S. Colombel J.F. Rachmilewitz D. Wolf D.C. Olson A. Bao W. Hanauer S.B. Comparison of Scheduled and Episodic Treatment Strategies of Infliximab in Crohn's Disease Gastroenterology 2004 126 2 402-413 DOI 10.1053/j.gastro.2003.11.014 43 Rutgeerts P, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126(2):402-413 (Pubitemid 38182297)
44. Regueiro M. Siemanowski B. Kip K.E. Plevy S. Infliximab dose intensification in Crohn's disease Inflammatory Bowel Diseases 2007 13 9 1093-1099 DOI 10.1002/ibd.20177 44 Regueiro M, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 2007;13:1093-1099 (Pubitemid 47402592)
45. Schnitzler F, et al. Flexibility in interval and dosing of infliximab enables maintained response of patients with Crohn's disease. Gastroenterology. 2008;134(Suppl 1):A-658.
46. Sandborn W, et al. Benefits of dosage adjustment with adalimubab in Crohn's disease: an analysis of the CHARM trial. Gastroenterology. 2008;134(Suppl 1):A-347.
47. Schreiber S, et al. Efficacy and tolerability of certolizumab pegol are sustained over 1 months: data from PRECISE 2 and its extension studies (PRECISE 3 and 4). Gastroenterology. 2008;134(Suppl 1):A-490.
48. Colombel J. Sandborn W.J. Rutgeerts P. Enns R. Hanauer S.B. Panaccione R. Schreiber S. Byczkowski D. Li J. Kent J.D. Pollack P.F. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial Gastroenterology 2007 132 1 52-65 DOI 10.1053/j.gastro.2006.11. 041, PII S0016508506025224 48 Colombel J-F, et al. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial. Gastroenterology. 2007;132(1):52-65. (Pubitemid 46108762)
49. Schreiber S. Khaliq-Kareemi M. Lawrance I.C. Thomsen O.O. Hanauer S.B. McColm J. Bloomfield R. Sandborn W.J. Maintenance therapy with certolizumab pegol for Crohn's disease New England Journal of Medicine 2007 357 3 239-250 http://content.nejm.org/cgi/reprint/357/3/239.pdf DOI 10.1056/NEJMoa062897 49 Schreiber S, et al. Maintenance Therapy with Certolizumab Pegol for Crohn's Disease. N Engl J Med. 2007;357(3):239-250 (Pubitemid 47080388)
50. Sandborn W.J. Rutgeerts P. Enns R. Hanauer S.B. Colombel J.-F. Panaccione R. D'Haens G. Li J. Rosenfeld M.R. Kent J.D. Pollack P.F. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial Annals of Internal Medicine 2007 146 12 829-838 http://www.annals.org/cgi/ reprint/146/12/829.pdf 50 Sandborn WJ, et al. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial. Ann Intern Med. 2007;146(12):829-838 (Pubitemid 351650483)
51. Vermeire S, et al. Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the Welcome study. Gastroenterology. 2008;134:A-67.
52. Mozziconacci N, et al. Efficacy of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF. Gastroenterology. 2008;134:A-663.
53. Oussalah A, et al. Adalimubab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-center experience. Aliment Pharmacol Ther. 2009;29:416-423